Dendritic cell vaccination and immune monitoring (original) (raw)

Dendritic Cells in Cancer Immunotherapy

Edgar Engleman

Annual Review of Immunology, 2000

View PDFchevron_right

Exploiting dendritic cells in the development of cancer vaccines

Enrico Proietti

Expert Review of Vaccines, 2013

View PDFchevron_right

Dendritic cell preparation for immunotherapeutic interventions

Marc Grégoire

2009

View PDFchevron_right

Dendritic cells in cancer immunology and immunotherapy

Marta Santisteban

Nature Reviews Immunology, 2019

View PDFchevron_right

Dendritic Cell Vaccination in Metastatic Melanoma Turns “Non-T Cell Inflamed” Into “T-Cell Inflamed” Tumors

Massimo Framarini

Frontiers in Immunology

View PDFchevron_right

Maturation of Dendritic Cells Is a Prerequisite for Inducing Immune Responses in Advanced Melanoma Patients

I Jolanda Vries, Nicole Scharenborg

Clinical Cancer Research

View PDFchevron_right

Guiding the “misguided” - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours

Christina To

European Journal of Immunology, 2011

View PDFchevron_right

Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Responses

Jean Davoust

The Journal of Immunology, 2000

View PDFchevron_right

Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Annemiek Boer

Clinical Cancer Research, 2011

View PDFchevron_right

Dendritic cells in cancer vaccines

Peter Brossart

Experimental Hematology, 2001

View PDFchevron_right

Dendritic cells and tumor immunity

Georg Varga

Seminars in Immunology, 2001

View PDFchevron_right

Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG, Adema GJBiodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59: 3340-3345

Annemiek Boer

Cancer Research

View PDFchevron_right

Dendritic cell vaccines in melanoma: From promise to proof?

Danita Schuurhuis, I Jolanda Vries, Gosse Adema, Erik Aarntzen

Critical Reviews in Oncology/Hematology, 2008

View PDFchevron_right

Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results

Gosse Adema

Annals of Oncology, 2004

View PDFchevron_right

Dendritic Cell-Based Vaccines in Cancer

H. kim Lyerly

American Journal of Cancer, 2002

View PDFchevron_right

Dendritic Cells in Antitumor Immune Responses

Jay Berzofsky

Cellular Immunology, 1996

View PDFchevron_right

Enhanced Antitumor Immunity Elicited by Dendritic Cell Vaccines Is a Result of Their Ability to Engage Both CTL and IFNγ-Producing NK Cells

Jeanette Boudreau

Molecular …, 2007

View PDFchevron_right

Editorial: Dendritic cell-primed T cells in anti-tumor immune responses and relevant vaccine strategies

yunfeng ma

Frontiers in Immunology

View PDFchevron_right

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection

A. Tuettenberg, Helmut Jonuleit

International Journal of Cancer, 2001

View PDFchevron_right

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

Annemiek Boer

OncoImmunology, 2016

View PDFchevron_right

Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens

DE YANG

View PDFchevron_right

Unpulsed dendritic cells induce broadly applicable anti-tumor immunity in mice

Albert DeLeo

Cancer Biology & Therapy, 2005

View PDFchevron_right

Prolonged Survival of Dendritic Cell-Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor -Expressing T Cells

Diego Reyes, M. Larrondo, Francisco Moya

Journal of Clinical Oncology, 2009

View PDFchevron_right

Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells

Diego Reyes

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009

View PDFchevron_right

Dendritic cells and cancer immunotherapy

Mireille Lahoud

Current Opinion in Immunology, 2014

View PDFchevron_right

Induction of cytotoxic T lymphocytes primed with Tumor RNA-loaded Dendritic Cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design

Reza Malekzadeh

BMC Cancer, 2010

View PDFchevron_right

Schreurs, MW, Eggert, AA, de Boer, AJ, Vissers, JL, van Hall, T, Offringa, R et al.. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 60: 6995-7001

Annemiek Boer

Cancer Research

View PDFchevron_right

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells

Carlos Alfaro

Experimental Hematology, 2002

View PDFchevron_right

Targeting dendritic cells for priming cellular immune responses

Éva Rajnavölgyi, Peter Gogolak

Journal of Molecular Recognition, 2003

View PDFchevron_right

Tumoricidal activity of human dendritic cells

Evelien Smits

Trends in Immunology, 2014

View PDFchevron_right